All News
What is D2T PsA?
A proposal of definition in ABST0777
Thoughts:
A lot of features are extrapolated from the EULAR RA definition
RA & PsA population are hardly comparable
Lack of emphasis more problematic domains ie. dactylitis
Further work is required
@RheumNow #ACR23 https://t.co/A28e6XBME3
Aurelie Najm ( View Tweet)
DRESS-PS study LTE. 12 month observational extension. 114 patients PsA/AxSpA. Essentially patients TNFi tapered or not in T2T fashion. TNFi dose remained lower in tapering group but it is consistently creeping back up. Abstr#0775 @RheumNow #ACR23 https://t.co/aYoOl6Ccin https://t.co/BtMR95lIfs
Richard Conway ( View Tweet)
Fascinating how upadacitinib may well have an effect on pain in RA, beyond inflammation.
Now seen similar for bari in RA & guselkumab in PsA. And, if real, for some people could be a massive get. Love to see dedicated studies
SELECT-COMPARE post-hoc #ACR23 ABST0429 @RheumNow https://t.co/Tk278mGJYY
David Liew drdavidliew ( View Tweet)
MEDIPSA: probiotic vs PBO RCT in PsA
12 weeks
Using strains Bifidobacterium and Lactobacillus
No effect on DA or PROMs in PsA
No effect on gut parameters either
Good safety profile
Wrong strains or not an generally efficient intervention?
ABST0778 @RheumNow #ACR23 https://t.co/RPgT7LoRgC
Aurelie Najm ( View Tweet)
What do you think of CAR T Rx in severe #SLE? @RheumNow @ACRheum #ACR23
Janet Pope ( View Tweet)
Ab#0596 #ACR23 @RheumNow
R Furie on Decravacitinib in SLE
48wk double-blind trial. PBO v DEU 3mgBID, 6 mgBID,12 mg qd
Higher response, faster time to SRI(4), BICLA and dual response v PBO. More likely to sustain response from w32-48. https://t.co/M34d3nQmwv
Eric Dein ( View Tweet)
LEGACY Cohort - Rx monitoring AZA/Tacro in SLE pregnancy
Ab#0586 #ACR23 @RheumNow
70 pregnancie. 33% prescribed AZA, 9% TAC
AZA - 91% subtherapeutic or non-adherent
More likely in non-Caucasian, on steroids, longer SLE duration, prior lupus nephritis
TAC - 3/6 therapeutic levels
Eric Dein ( View Tweet)
Do probiotics improve psoriatic arthritis?
Unfortunately no difference in disease activity compared to placebo.
Limited effects on gut dysbiosis
Minor effects on T cell composition
@RheumNow #ACR23 Abs#0778 https://t.co/JuBesyfnV2
Robert B Chao, MD ( View Tweet)
Targeted OX40L (co-stimulatory APC protein w/ possible polymorphisms in SLE) study by Womba et al, found OX40L targeted CAR-Tregs had superior in vitro suppression of activated T cells & dendritic cells relative to Control-Tregs. #ACR23 Abs 0799 https://t.co/GgCGGIvhHF @rheumnow https://t.co/GZMEUCTooh
Dr. Rachel Tate ( View Tweet)
Should the cost of #CAR-T stop us from considering in severe refractory #lupus? So far update of German group show remission - drug free and great safety. But hold on..we need RCTs with an active control and longer f/u, but I am impressed! #ACR23 #ACRbest @ACRheum @RheumNow #784 https://t.co/mRMWLCbpCY
Janet Pope ( View Tweet)
Klein et al. 205 RA-ILD. MUC5B not significantly associated survival, although wide CIs, aHR 0.75 (0.45, 1.24). Abstr#0772 #ACR23 @RheumNow https://t.co/ZfIIr2BbbR https://t.co/47DPYWNpL9
Richard Conway ( View Tweet)
#ACR23 tidbits from Sunday @ACRheum @RheumNow
1 Less steroids better w other #Rx in #GCA, #PMR, #SLE #nephritis, #nonrenal #lupus BUT NOT in Severe GCA
2 Trend for combined immune modulators in #lupus GN or w a #CNI
3 #HCQ is better than sliced bread in #SLE aim for drug level
Janet Pope ( View Tweet)
#ACR23
Lower persistance of TNFi in women than men in Psa👍🇫🇷🇫🇷🇫🇷 CHU Mondor
@RheumNow https://t.co/27OVLz4aZN
Dellal ( View Tweet)
Biologic persistance rates consistently lower in women vs men with PsA. 52% vs 62% @ 1 year. Some statistically significant, but really it is a consistent message across drugs. We urgently need research on the reasons. Abstr#0779 #ACR23 @RheumNow https://t.co/Kfk3k3LJ44 https://t.co/SmiOnt7D4d
Richard Conway ( View Tweet)
Risk factor for 1st Thrombosis in OB APS
Ab#0115 #ACR23 @RheumNow
186 OAPS pts, followed mean 5.4 yrs. 11 thrombotic events
Risk factors: Triple pos APS Abs (OR 11.6), hypocomplementemia (OR 9)
Low dose Aspirin (OR 0.14), HCQ (OR 0.11) reduced thrombosis
#ACRBest https://t.co/y4KaEAZzA7
Eric Dein ( View Tweet)
🆕 Imaging modality: MSOT multispectral optoacoustic tomography
Findings PsA enthesis
-Hyperemia ↗️ oxygenation So2 and Hboxy
-Reduction Collagen concentration
-Lipids substitution
But surprise PSO pts display similar signs despite abs of symptoms!
@RheumNow ABST0750 #ACR23 https://t.co/qWMvmIRd7j
Aurelie Najm ( View Tweet)
#ACR23 Convergence Preview
https://t.co/oCdYnS1HdC https://t.co/A6klTchrrG
Dr. John Cush RheumNow ( View Tweet)
FAPα possible therapeutic biomarker target of pathogenic fibroblasts. #ACR23 Abs 0802 demonstrates potential therapeutic efficacy of fibroblast-targeted immunotherapy as a novel treatment in inflammatory disease. https://t.co/ZGUfC6PZxa @rheumnow https://t.co/jj9BeuvTuc
Dr. Rachel Tate ( View Tweet)
Abs#518 @RheumNow #ACR23
Deodhar: TOFA in AS, by b/l CRP levels
30% nml CRP (<5 mg/L) v 70% Elevated
At wk 12, TOFA >> PBO regardless of b/l CRP
Difference in response: greater in pts w elevated CRP
Safety rates: elev. CRP c/w PBO, but nml CRP had trend of high AEs for tofa v PBO https://t.co/b9NRNkU8ub
Eric Dein ( View Tweet)
Are Long-term NSAIDs safe in AS?
Ab#0528 #ACR23 @RheumNow
19,775 AS pts vs 59,325 controls.
Incidence of 16.9, 13.8 per 1,000 person-yrs, respectively
Long-term use of NSAIDs increased risk of CVD in non-AS control (aHR 1.64), but did NOT in AS pts (aHR 1.06)
Eric Dein ( View Tweet)